TNYA
Tenaya Therapeutics, Inc. NASDAQ Listed Jul 30, 2021$0.70
Pre-mkt
$0.66
-5.71%
Mkt Cap $107.1M
52w Low $0.55
9.7% of range
52w High $2.10
50d MA $0.77
200d MA $1.00
P/E (TTM)
—
EV/EBITDA
—
P/B
0.9x
Debt/Equity
0.1x
ROE
-73.5%
P/FCF
-1.6x
RSI (14)
27.30
ATR (14)
$0.05
Beta
3.00
50d MA
$0.77
200d MA
$1.00
Avg Volume
4.3M
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
CIK (SEC)
Phone
650 825 6900
171 Oyster Point Boulevard · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | AMC | -0.13 | -0.12 | +7.7% | 0.86 | -1.0% | +4.0% | -4.5% | +0.6% | +0.0% | -4.1% | — |
| Nov 10, 2025 | AMC | -0.15 | -0.12 | +20.0% | 1.43 | +0.0% | -0.7% | +8.5% | -11.0% | -2.9% | -5.3% | — |
| Aug 6, 2025 | AMC | -0.20 | -0.14 | +30.0% | 0.67 | +0.8% | -1.7% | +0.9% | +1.8% | +11.1% | +13.8% | — |
| May 7, 2025 | AMC | -0.18 | -0.24 | -33.3% | 0.45 | +1.1% | -2.1% | -6.1% | -0.7% | -4.1% | -1.6% | — |
| Mar 10, 2025 | AMC | -0.31 | -0.28 | +9.7% | 0.51 | +2.4% | +6.8% | +11.2% | +11.6% | +4.3% | +4.4% | — |
| Nov 6, 2024 | AMC | -0.37 | -0.30 | +18.9% | 2.23 | +4.9% | +12.1% | +10.4% | -6.9% | -14.0% | -5.4% | — |
| Aug 8, 2024 | AMC | -0.40 | -0.34 | +15.0% | 2.68 | +1.5% | -1.1% | +2.6% | +12.1% | -7.2% | +6.0% | — |
| May 14, 2024 | AMC | -0.43 | -0.40 | +7.0% | 4.40 | +4.3% | -3.4% | +0.0% | +9.6% | -8.8% | -1.6% | — |
| Mar 18, 2024 | AMC | -0.45 | -0.40 | +11.1% | 4.82 | -0.8% | -6.0% | +8.2% | -2.4% | -1.3% | +3.0% | — |
| Nov 8, 2023 | AMC | -0.47 | -0.39 | +17.0% | 1.96 | +4.6% | -3.6% | -1.6% | -1.1% | +4.9% | -5.7% | — |
| Aug 9, 2023 | AMC | -0.51 | -0.45 | +11.8% | 4.18 | +1.4% | +5.5% | +0.2% | -7.0% | -4.9% | -1.8% | — |
| May 10, 2023 | AMC | -0.60 | -0.43 | +28.3% | 6.80 | +2.6% | +7.6% | -7.5% | +3.4% | -3.9% | +6.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12 | Chardan Capital | Maintains | Buy → Buy | — | $0.86 | $0.85 | -1.0% | +4.0% | -4.5% | +0.6% | +0.0% | -4.1% |
| Dec 18 | Canaccord Genuity | Maintains | Buy → Buy | — | $0.67 | $0.70 | +4.7% | +0.1% | +4.9% | +8.1% | -7.1% | +5.9% |
| Dec 12 | Chardan Capital | Maintains | Buy → Buy | — | $1.36 | $1.05 | -22.8% | -37.5% | -6.2% | -4.0% | -12.8% | +0.1% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.36 | $1.05 | -22.8% | -37.5% | -6.2% | -4.0% | -12.8% | +0.1% |
| Nov 10 | Chardan Capital | Maintains | Buy → Buy | — | $1.28 | $1.20 | -6.2% | +11.7% | -0.7% | +8.5% | -11.0% | -2.9% |
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.13 | $1.12 | -0.9% | -4.4% | +9.3% | +5.1% | +8.9% | +3.7% |
| Aug 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.08 | $1.11 | +2.8% | +1.9% | +2.7% | +0.0% | -4.4% | +9.3% |
| Aug 7 | Chardan Capital | Maintains | Buy → Buy | — | $0.67 | $0.68 | +0.8% | -1.7% | +0.9% | +1.8% | +11.1% | +13.8% |
| May 9 | Chardan Capital | Maintains | Buy → Buy | — | $0.44 | $0.45 | +2.1% | -6.1% | -0.7% | -4.1% | -1.6% | +12.7% |
| Apr 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.46 | $0.48 | +4.8% | +6.6% | -1.5% | -0.2% | -1.7% | +7.4% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.64 | $0.64 | +0.1% | -11.3% | -4.6% | +4.0% | -8.1% | -4.1% |
| Mar 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $0.60 | $0.63 | +4.3% | +11.6% | +4.3% | +4.4% | -6.5% | +2.2% |
| Mar 12 | Morgan Stanley | Maintains | Overweight → Overweight | — | $0.54 | $0.57 | +5.0% | +11.2% | +11.6% | +4.3% | +4.4% | -6.5% |
| Mar 12 | Chardan Capital | Maintains | Buy → Buy | — | $0.54 | $0.57 | +5.0% | +11.2% | +11.6% | +4.3% | +4.4% | -6.5% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.51 | $0.52 | +2.4% | +6.8% | +11.2% | +11.6% | +4.3% | +4.4% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.06 | $1.04 | -1.9% | -0.9% | -1.9% | +1.0% | -3.8% | -3.5% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.50 | $1.55 | +3.3% | -4.7% | +2.8% | -5.4% | +0.7% | -7.1% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.41 | $1.42 | +0.7% | -12.8% | +14.6% | +18.4% | -4.8% | +4.4% |
| Dec 18 | Chardan Capital | Maintains | Buy → Buy | — | $1.41 | $1.42 | +0.7% | -12.8% | +14.6% | +18.4% | -4.8% | +4.4% |
| Nov 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.96 | $3.09 | +4.4% | +11.1% | +0.0% | +8.5% | +0.3% | -3.4% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.38 | $2.45 | +2.9% | +24.4% | +11.1% | +0.0% | +8.5% | +0.3% |
| Nov 7 | Chardan Capital | Maintains | Buy → Buy | — | $2.23 | $2.34 | +4.9% | +12.1% | +10.4% | -6.9% | -14.0% | -5.4% |
| Oct 18 | Canaccord Genuity | Maintains | Buy → Buy | — | $2.15 | $2.21 | +2.8% | -5.1% | -5.9% | -0.5% | -2.1% | -2.1% |
| Oct 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.15 | $2.21 | +2.8% | -5.1% | -5.9% | -0.5% | -2.1% | -2.1% |
| Jul 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.92 | $2.88 | -1.4% | +2.1% | +0.7% | +2.3% | +14.0% | +0.3% |
| May 16 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.25 | $4.25 | +0.0% | +0.0% | +9.6% | -8.8% | -1.6% | +5.7% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.40 | $4.59 | +4.3% | -3.4% | +0.0% | +9.6% | -8.8% | -1.6% |
| Mar 21 | Chardan Capital | Maintains | Buy → Buy | — | $4.90 | $4.99 | +1.8% | -2.4% | -1.3% | +3.0% | -0.6% | +6.8% |
| Mar 20 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.53 | $4.52 | -0.2% | +8.2% | -2.4% | -1.3% | +3.0% | -0.6% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.82 | $4.78 | -0.8% | -6.0% | +8.2% | -2.4% | -1.3% | +3.0% |
| Oct 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.57 | $2.49 | -3.1% | -0.8% | +0.6% | -6.0% | -5.8% | +0.9% |
| Aug 14 | Chardan Capital | Maintains | Buy → Buy | — | $4.42 | $4.53 | +2.5% | -7.0% | -4.9% | -1.8% | -0.5% | +1.8% |
| Aug 11 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.41 | $4.36 | -1.1% | +0.2% | -7.0% | -4.9% | -1.8% | -0.5% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.18 | $4.24 | +1.4% | +5.5% | +0.2% | -7.0% | -4.9% | -1.8% |
| Aug 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $4.18 | $4.24 | +1.4% | +5.5% | +0.2% | -7.0% | -4.9% | -1.8% |
| May 12 | Chardan Capital | Maintains | Buy → Buy | — | $7.32 | $7.54 | +3.0% | -7.5% | +3.4% | -3.9% | +6.2% | +1.0% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.80 | $6.98 | +2.6% | +7.6% | -7.5% | +3.4% | -3.9% | +6.2% |
| Mar 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.34 | $3.15 | -5.7% | -12.6% | -10.6% | +9.2% | -8.1% | +0.2% |
| Mar 9 | Chardan Capital | Maintains | Buy → Buy | — | $3.34 | $3.15 | -5.7% | -12.6% | -10.6% | +9.2% | -8.1% | +0.2% |
| Jan 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $2.83 | $2.93 | +3.5% | +13.8% | +0.6% | -3.7% | +9.6% | -1.5% |
| Nov 11 | Chardan Capital | Maintains | Buy → Buy | — | $2.04 | $1.95 | -4.4% | +30.9% | +11.6% | -1.7% | +8.9% | -21.6% |
| Nov 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.92 | $2.01 | +4.7% | -5.2% | +4.9% | +6.8% | +30.9% | +11.6% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $5.49 | $5.63 | +2.6% | -0.5% | +2.7% | +2.1% | -7.5% | -5.1% |
| Jun 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.38 | $5.90 | +9.7% | +1.1% | +0.0% | -0.4% | +9.8% | +4.4% |
| May 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.00 | $7.27 | +3.9% | +3.3% | -10.2% | -13.4% | +18.3% | -3.2% |
| Aug 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $23.35 | $23.80 | +1.9% | +2.5% | -6.6% | +5.1% | +13.5% | -3.3% |
| Aug 24 | Chardan Capital | Maintains | Buy → Buy | — | $23.35 | $23.80 | +1.9% | +2.5% | -6.6% | +5.1% | +13.5% | -3.3% |
| Aug 24 | Piper Sandler | Maintains | Overweight → Overweight | — | $23.35 | $23.80 | +1.9% | +2.5% | -6.6% | +5.1% | +13.5% | -3.3% |
| Aug 24 | TD Cowen | Maintains | Outperform → Outperform | — | $23.35 | $23.80 | +1.9% | +2.5% | -6.6% | +5.1% | +13.5% | -3.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 18, 2026 | Tingley Whittemore | Chief Medical Officer | Sell | 3,121 | $0.79 | $2K | 215,497 | +2.62% | +1.29% |
| May 18, 2026 | Higa Tomohiro | SVP, Finance | Sell | 1,485 | $0.79 | $1K | 118,267 | +2.62% | +1.29% |
| May 18, 2026 | Ali Faraz | Chief Executive Officer | Sell | 3,390 | $0.79 | $3K | 440,014 | +2.62% | +1.29% |
8-K
Unknown — 8-K Filing
Tenaya Therapeutics (TNYA) is advancing its cardiac disease pipeline with positive momentum, suggesting potential near-term clinical catalysts that could justify its clinical-stage valuation if development programs succeed.
Mar 11
8-K · 1.01
!! High
Tenaya Therapeutics, Inc. -- 8-K 1.01: Collaboration Agreement
Tenaya Therapeutics secured a $10 million collaboration agreement with Alnylam Pharmaceuticals to develop RNA-based therapeutics, providing funding and potential revenue expansion for the smaller biotech firm.
Mar 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 8,482,288 | $6M | New | Mar 2026 |
| 2 | Millennium Management | 5,456,666 | $4M | Added | Mar 2026 |
| 3 | Citadel Advisors Llc | 4,200,000 | $3M | — | Mar 2026 |
| 4 | Renaissance Technologies Llc | 3,713,761 | $3M | Added | Mar 2026 |
| 5 | Marshall Wace, Llp | 2,705,390 | $2M | Added | Mar 2026 |
| 6 | Kalehua Capital Management Llc | 2,000,000 | $1M | — | Mar 2026 |
| 7 | Adar1 Capital Management, Llc | 1,507,800 | $1M | New | Mar 2026 |
| 8 | Two Sigma Investments, Lp | 1,280,390 | $887K | Added | Mar 2026 |
| 9 | Alphabet Inc. | 915,705 | $650K | — | Dec 2025 |
| 10 | Raiffeisen Bank International Ag | 900,000 | $630K | Added | Dec 2025 |
| 11 | Mirador Capital Partners Lp | 886,917 | $614K | Added | Mar 2026 |
| 12 | Jane Street Group, Llc | 678,460 | $483K | Added | Dec 2025 |
| 13 | Ubs Group Ag | 665,180 | $460K | Added | Mar 2026 |
| 14 | Stepstone Group Lp | 462,163 | $319K | — | Mar 2026 |
| 15 | Morgan Stanley | 416,862 | $297K | Added | Dec 2025 |
| 16 | Northern Trust Corp | 310,654 | $215K | Added | Mar 2026 |
| 17 | Susquehanna International Group, Llp | 308,772 | $214K | Added | Mar 2026 |
| 18 | Marex Group Plc | 235,500 | $163K | Added | Mar 2026 |
| 19 | Acadian Asset Management Llc | 169,780 | $116K | New | Mar 2026 |
| 20 | Castleview Partners, Llc | 153,137 | $106K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 13
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | iShares Biotechnology ETF | 1,200,002 | $831K | Mar 2026 |
| 2 | Fidelity Extended Market Index Fund | 553,214 | $311K | Feb 2026 |
| 3 | Ultra-Small Company Market Fund | 175,000 | $121K | Mar 2026 |
| 4 | Fidelity Total Market Index Fund | 175,218 | $98K | Feb 2026 |
| 5 | Fidelity Series Total Market Index Fund | 146,964 | $83K | Feb 2026 |
| 6 | Fidelity Nasdaq Composite Index Fund | 120,429 | $68K | Feb 2026 |
| 7 | Schwab Total Stock Market Index Fund | 50,000 | $39K | Jan 2026 |
| 8 | Victory Extended Market Index Fund | 15,726 | $12K | Jan 2026 |
| 9 | Invesco Nasdaq Biotechnology ETF | 9,284 | $5K | Feb 2026 |
| 10 | ProShares Ultra Nasdaq Biotechnology | 7,688 | $4K | Feb 2026 |
| 11 | AST Small-Cap Equity Portfolio | 4,770 | $3K | Dec 2025 |
| 12 | Avantis Total Equity Markets ETF | 3,673 | $2K | Feb 2026 |
| 13 | Guggenheim Active Allocation Fund | 153 | $86 | Feb 2026 |
Valuation
Market Cap
$107.1M
Enterprise Value
$14.3M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.02x
P/B
0.87x
P/S
475.91x
P/FCF
-1.55x
EV/EBITDA
—
Shares Out
153.0M
Financials (TTM)
Revenue
$225K
Net Income
-$83.0M
EBITDA
-$75.5M
Free Cash Flow
-$68.9M
Op Cash Flow
-$68.3M
EPS Basic
$-0.59
EPS Diluted
$-0.47
EPS Forward
$-0.43
Gross Margin
144.9%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$146.9M
Total Liab.
$23.7M
Total Equity
$123.3M
Cash
$100.5M
LT Debt
$7.8M
Book Value/Sh
$0.81
Debt/Equity
0.09x
Current Ratio
6.84
Quick Ratio
6.84
Returns & Growth
ROE
-73.5%
ROA
-61.7%
ROIC
-69.4%
Rev Growth YoY
+0.0%
EPS Growth YoY
+55.0%
Price Returns
2W
-7.1%
1M
+25.7%
3M
+54.7%
6M
-37.9%
12M
+88.9%
Technicals
52W High
$2.10
52W Low
$0.55
50d MA
$0.77
200d MA
$1.00
RSI (14)
27.30
ATR (14)
$0.05
Beta
3.00
Avg Volume
4.3M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$2.33
High
$3.00
Low
$2.00
Median
$2.00
Data updated apr 27, 2026 5:14am
· Source: financialmodelingprep.com